Biblio

Export 330 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Keyword is T  [Clear All Filters]
Journal Article
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
D. Renard, Collombier, L., Demattei, C., Wacongne, A., Charif, M., Ayrignac, X., Azakri, S., Gaillard, N., Boudousq, V., Lehmann, S., de Champfleur, N. Menjot, and Thouvenot, E., “Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.
C. Giuseppina Bonomi, Assogna, M., Di Donna, M. Gaia, Bernocchi, F., De Lucia, V., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. Biagio, Koch, G., Martorana, A., and Motta, C., “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E., “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
O. Godefroy, Bakchine, S., Verny, M., Delabrousse-Mayoux, J. - P., Roussel, M., and Pere, J. - J., “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.
J. R. Hall, Wiechmann, A., Johnson, L. A., Edwards, M., and O'Bryant, S. E., “Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1485-1492, 2018.
A. - M. C. Leiby, Scambray, K. A., Nguyen, H. L., Basith, F., Fakhraee, S., Melikyan, Z. A., Bukhari, S. A., Montine, T. J., Corrada, M. M., Kawas, C. H., and S Sajjadi, A., “Characterizing Limbic-Predominant Age-Related TDP-43 Encephalopathy Without Alzheimer's Disease and Lewy Body Dementia in the Oldest Old: A Case Series.”, J Alzheimers Dis, vol. 96, no. 1, pp. 113-124, 2023.
A. - M. C. Leiby, Scambray, K. A., Nguyen, H. L., Basith, F., Fakhraee, S., Melikyan, Z. A., Bukhari, S. A., Montine, T. J., Corrada, M. M., Kawas, C. H., and S Sajjadi, A., “Characterizing Limbic-Predominant Age-Related TDP-43 Encephalopathy Without Alzheimer's Disease and Lewy Body Dementia in the Oldest Old: A Case Series.”, J Alzheimers Dis, vol. 96, no. 1, pp. 113-124, 2023.
A. Madhavan, Schwarz, C. G., Duffy, J. R., Strand, E. A., Machulda, M. M., Drubach, D. A., Kantarci, K., Przybelski, S. A., Reid, R. I., Senjem, M. L., Gunter, J. L., Apostolova, L. G., Lowe, V. J., Petersen, R. C., Jack, C. R., Josephs, K. A., and Whitwell, J. L., “Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 633-43, 2016.
M. Liu, Li, M., He, J., He, Y., Yang, J., and Sun, Z., “Chiral Amino Acid Profiling in Serum Reveals Potential Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 1, pp. 291-301, 2023.
D. E. Moss, Perez, R. G., and Kobayashi, H., “Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1285-1294, 2017.
H. Qiu, Zhong, R., Liu, H., Zhang, F., Li, S., and Le, W., “Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
V. Bonet-Costa, Herranz-Pérez, V., Blanco-Gandía, M. C., Mas-Bargues, C., Inglés, M., Garcia-Tarraga, P., Rodriguez-Arias, M., Miñarro, J., Borras, C., Garcia-Verdugo, J. Manuel, and Viña, J., “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
I. Álvarez, Aguilar, M., González, J. Manuel, Ysamat, M., Lorenzo-Bosquet, C., Alonso, A., Tartari, J. Pablo, Romero, S., Diez-Fairen, M., Carcel, M., Pujalte, F., and Pastor, P., “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
J. M. Walker, Gonzales, M. M., Goette, W., Farrell, K., Iii, C. L. White, Crary, J. F., and Richardson, T. E., “Cognitive and Neuropsychological Profiles in Alzheimer's Disease and Primary Age-Related Tauopathy and the Influence of Comorbid Neuropathologies.”, J Alzheimers Dis, vol. 92, no. 3, pp. 1037-1049, 2023.
C. M. Huber, Yee, C., May, T., Dhanala, A., and Mitchell, C. S., “Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.”, J Alzheimers Dis, vol. 61, no. 1, pp. 265-281, 2018.
M. Balietti, Giuli, C., Fattoretti, P., Fabbietti, P., Postacchini, D., and Conti, F., “Cognitive Stimulation Modulates Platelet Total Phospholipases A2 Activity in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 957-62, 2016.
C. E. Gleason, Norton, D., Anderson, E. D., Wahoske, M., Washington, D. T., Umucu, E., Koscik, R. L., N Dowling, M., Johnson, S. C., Carlsson, C. M., and Asthana, S., “Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.”, J Alzheimers Dis, vol. 61, no. 1, pp. 79-89, 2018.

Pages